{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:07:37Z","timestamp":1761523657083},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2012,3,20]],"date-time":"2012-03-20T00:00:00Z","timestamp":1332201600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s00384-012-1446-2","type":"journal-article","created":{"date-parts":[[2012,3,19]],"date-time":"2012-03-19T06:46:43Z","timestamp":1332139603000},"page":"1325-1332","source":"Crossref","is-referenced-by-count":25,"title":["Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study"],"prefix":"10.1007","volume":"27","author":[{"given":"Pei-Long","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-Fa","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,20]]},"reference":[{"issue":"2","key":"1446_CR1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","volume":"56","author":"A Jemal","year":"2006","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106\u2013130","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1446_CR2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/1055-9965.243.14.1","volume":"14","author":"L Yang","year":"2005","unstructured":"Yang L, Parkin DM, Ferlay J, Li L, Chen Y (2005) Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 14(1):243\u2013250","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"1446_CR3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.critrevonc.2004.07.001","volume":"52","author":"LM Pasetto","year":"2004","unstructured":"Pasetto LM, Pucciarelli S, Agostini M, Rossi E, Monfardini S (2004) Neoadjuvant treatment for locally advanced rectal carcinoma. Crit Rev Oncol Hematol 52(1):61\u201371","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"1446_CR4","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1245\/s10434-008-9896-z","volume":"15","author":"RC Dresen","year":"2008","unstructured":"Dresen RC, Gosens MJ, Martijn H, Nieuwenhuijzen GA, Creemers GJ, Daniels-Gooszen AW, van den Brule AJ, van den Berg HA, Rutten HJ (2008) Radical resection after IORT-containing multimodality treatment is the most important determinant for outcome in patients treated for locally recurrent rectal cancer. Ann Surg Oncol 15(7):1937\u20131947","journal-title":"Ann Surg Oncol"},{"key":"1446_CR5","first-page":"CD002102","volume":"2","author":"RK Wong","year":"2007","unstructured":"Wong RK, Tandan V, De Silva S, Figueredo A (2007) Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev 2:CD002102","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"1446_CR6","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1056\/NEJMoa010580","volume":"345","author":"E Kapiteijn","year":"2001","unstructured":"Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ, Dutch Colorectal Cancer Group (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345(9):638\u2013646","journal-title":"N Engl J Med"},{"issue":"24","key":"1446_CR7","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1200\/JCO.2005.02.113","volume":"23","author":"JF Bosset","year":"2005","unstructured":"Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Briffaux A, Collette L (2005) Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results\u2014EORTC 22921. J Clin Oncol 23(24):5620\u20135627","journal-title":"J Clin Oncol"},{"issue":"11","key":"1446_CR8","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa060829","volume":"355","author":"JF Bosset","year":"2006","unstructured":"Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC, EORTC Radiotherapy Group Trial 22921 (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355(11):1114\u20131123","journal-title":"N Engl J Med"},{"issue":"28","key":"1446_CR9","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","volume":"24","author":"JP G\u00e9rard","year":"2006","unstructured":"G\u00e9rard JP, Conroy T, Bonnetain F, Bouch\u00e9 O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24(28):4620\u20134625","journal-title":"J Clin Oncol"},{"issue":"4","key":"1446_CR10","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.thromres.2009.06.008","volume":"125","author":"MM Beckers","year":"2010","unstructured":"Beckers MM, Ruven HJ, Seldenrijk CA, Prins MH, Biesma DH (2010) Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer. Thromb Res 125(4):318\u2013321","journal-title":"Thromb Res"},{"issue":"3\u20134","key":"1446_CR11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000127383","volume":"73","author":"O Dupuis","year":"2007","unstructured":"Dupuis O, Vie B, Lledo G, Hennequin C, Noirclerc M, Bennamoun M, Jacob JH (2007) Preoperative treatment combining capecitabine with radiation therapy in rectal cancer: a GERCOR Phase II Study. Oncology 73(3\u20134):169\u2013176","journal-title":"Oncology"},{"key":"1446_CR12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1748-717X-5-88","volume":"5","author":"V Velenik","year":"2010","unstructured":"Velenik V, Oblak I, Anderluh F (2010) Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer. Radiat Oncol 5:88","journal-title":"Radiat Oncol"},{"issue":"5","key":"1446_CR13","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/annonc\/mdn719","volume":"20","author":"C Carlomagno","year":"2009","unstructured":"Carlomagno C, Farella A, Bucci L, D\u2019Armiento FP, Pesce G, Pepe S, Cannella L, Pacelli R, De Stefano A, Solla R, D\u2019Armiento MR, De Placido S (2009) Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. Ann Oncol 20(5):906\u2013912","journal-title":"Ann Oncol"},{"issue":"3","key":"1446_CR14","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ijrobp.2008.01.020","volume":"72","author":"MG Fakih","year":"2008","unstructured":"Fakih MG, Bullarddunn K, Yang GY, Pendyala L, Toth K, Andrews C, Rustum YM, Ross ME, Levea C, Puthillath A, Park YM, Rajput A (2008) Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 72(3):650\u2013657","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"1446_CR15","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/sj.bjc.6604042","volume":"97","author":"I Craven","year":"2007","unstructured":"Craven I, Crellin A, Cooper R, Melcher A, Byrne P, Sebag-Montefiore D (2007) Preoperative radiotherapy combined with 5\u00a0days per week capecitabine chemotherapy in locally advanced rectal cancer. Br J Cancer 97(10):1333\u20131337","journal-title":"Br J Cancer"},{"issue":"14","key":"1446_CR16","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Cutsem Van","year":"2009","unstructured":"Van Cutsem E, K\u00f6hne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D\u2019Haens G, Pint\u00e9r T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408\u20131417","journal-title":"N Engl J Med"},{"issue":"4","key":"1446_CR17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337\u2013345","journal-title":"N Engl J Med"},{"issue":"2","key":"1446_CR18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.radonc.2004.12.021","volume":"74","author":"J Giralt","year":"2005","unstructured":"Giralt J, de las Heras M, Cerezo L, Eraso A, Hermosilla E, Velez D, Lujan J, Espin E, Rosello J, Maj\u00f3 J, Benavente S, Armengol M, de Torres I, Grupo Espa\u00f1ol de Investigacion Clinica en Oncologia Radioter\u00e1pica (GICOR) (2005) The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 74(2):101\u2013108","journal-title":"Radiother Oncol"},{"issue":"4","key":"1446_CR19","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/annonc\/mdl460","volume":"18","author":"JP Machiels","year":"2007","unstructured":"Machiels JP, Sempoux C, Scalliet P, Coche JC, Humblet Y, Van Cutsem E, Kerger J, Canon JL, Peeters M, Aydin S, Laurent S, Kartheuser A, Coster B, Roels S, Daisne JF, Honhon B, Duck L, Kirkove C, Bonny MA, Haustermans K (2007) Phase I\/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 18(4):738\u2013744","journal-title":"Ann Oncol"},{"issue":"5","key":"1446_CR20","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.ijrobp.2006.07.005","volume":"66","author":"RD Hofheinz","year":"2006","unstructured":"Hofheinz RD, Horisberger K, Woernle C, Wenz F, Kraus-Tiefenbacher U, K\u00e4hler G, Dinter D, Grobholz R, Heeger S, Post S, Hochhaus A, Willeke F (2006) Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys 66(5):1384\u20131390","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1446_CR21","first-page":"49","volume":"1","author":"TS Hong","year":"2007","unstructured":"Hong TS, Kachnic LA (2007) Preoperative chemoradiotherapy in the management of localized rectal cancer: the new standard. Gastrointest Cancer Res 1(2):49\u201356","journal-title":"Gastrointest Cancer Res"},{"issue":"17","key":"1446_CR22","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","volume":"359","author":"CS Karapetis","year":"2008","unstructured":"Karapetis CS, Khambata-Ford S, Jonker DJ, O\u2019Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359(17):1757\u20131765","journal-title":"N Engl J Med"},{"issue":"3","key":"1446_CR23","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/02841860903536010","volume":"49","author":"R Glynne-Jones","year":"2010","unstructured":"Glynne-Jones R, Mawdsley S, Harrison M (2010) Cetuximab and chemoradiation for rectal cancer\u2013is the water getting muddy? Acta Oncol 49(3):278\u2013286","journal-title":"Acta Oncol"},{"issue":"7","key":"1446_CR24","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/sj.bjc.6604297","volume":"98","author":"D Koeberle","year":"2008","unstructured":"Koeberle D, Burkhard R, von Moos R, Winterhalder R, Hess V, Heitzmann F, Ruhstaller T, Terraciano L, Neuweiler J, Bieri G, Rust C, Toepfer M (2008) Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer 98(7):1204\u20131209","journal-title":"Br J Cancer"},{"key":"1446_CR25","doi-asserted-by":"crossref","unstructured":"Glynne-Jones R, Falk S, Maughan TS, Meadows HM, Sebag-Montefiore D (2007) A phase I\/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study. Br J Cancer 551\u2013558","DOI":"10.1038\/sj.bjc.6603570"},{"issue":"2","key":"1446_CR26","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ijrobp.2009.07.1718","volume":"78","author":"C Weiss","year":"2010","unstructured":"Weiss C, Arnold D, Dellas K, Liersch T, Hipp M, Fietkau R, Sauer R, Hinke A, R\u00f6del C (2010) Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: a pooled analysis of three prospective phase I\u2013II trials. Int J Radiat Oncol Biol Phys 78(2):472\u2013478","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1446_CR27","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ijrobp.2006.02.050","volume":"65","author":"S Roels","year":"2006","unstructured":"Roels S, Duthoy W, Haustermans K, Penninckx F, Vandecaveye V, Boterberg T, De Neve W (2006) Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys 65(4):1129\u20131142","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1446_CR28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejso.2009.12.002","volume":"36","author":"V Velenik","year":"2010","unstructured":"Velenik V, Ocvirk J, Oblak I, Anderluh F (2010) A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol 36(3):244\u2013250","journal-title":"Eur J Surg Oncol"},{"key":"1446_CR29","doi-asserted-by":"crossref","unstructured":"R\u00f6del C, Martus P, Papadoupolos T, F\u00fczesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 8688\u20138696","DOI":"10.1200\/JCO.2005.02.1329"},{"issue":"5","key":"1446_CR30","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.ijrobp.2008.10.014","volume":"74","author":"K Horisberger","year":"2009","unstructured":"Horisberger K, Treschl A, Mai S, Barreto-Miranda M, Kienle P, Str\u00f6bel P, Erben P, Woernle C, Dinter D, K\u00e4hler G, Hochhaus A, Post S, Willeke F, Wenz F, Hofheinz RD, MARGIT (Mannheimer Arbeitsgruppe f\u00fcr Gastrointestinale Tumoren) (2009) Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. Int J Radiat Oncol Biol Phys 74(5):1487\u20131493","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1446_CR31","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ijrobp.2008.04.065","volume":"73","author":"F Bertolini","year":"2009","unstructured":"Bertolini F, Chiara S, Bengala C, Antognoni P, Dealis C, Zironi S, Malavasi N, Scolaro T, Depenni R, Jovic G, Sonaglio C, Rossi A, Luppi G, Conte PF (2009) Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 73(2):466\u2013472","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1446_CR32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.radonc.2004.12.018","volume":"74","author":"JG Eriksen","year":"2005","unstructured":"Eriksen JG, Steiniche T, Overgaard J, Danish Head and Neck Cancer study group (DAHANCA) (2005) The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study. Radiother Oncol 74(2):93\u2013100","journal-title":"Radiother Oncol"},{"issue":"3","key":"1446_CR33","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/sj.bjc.6606054","volume":"104","author":"JB Baker","year":"2011","unstructured":"Baker JB, Dutta D, Watson D, Maddala T, Munneke BM, Shak S, Rowinsky EK, Xu LA, Harbison CT, Clark EA, Mauro DJ, Khambata-Ford S (2011) Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer 104(3):488\u2013495","journal-title":"Br J Cancer"},{"issue":"2","key":"1446_CR34","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/annonc\/mdq704","volume":"22","author":"W Zhang","year":"2011","unstructured":"Zhang W, Labonte MJ, Lenz HJ (2011) KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: does treatment combination partner matter? Ann Oncol 22(2):484\u2013485","journal-title":"Ann Oncol"},{"issue":"10","key":"1446_CR35","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1158\/1078-0432.CCR-10-2273","volume":"17","author":"PP Grimminger","year":"2011","unstructured":"Grimminger PP, Danenberg P, Dellas K, Arnold D, R\u00f6del C, Machiels JP, Haustermans K, Debucquoy A, Velenik V, Sempoux C, Bracko M, H\u00f6lscher AH, Semrau R, Yang D, Danenberg K, Lenz HJ, Vallb\u00f6hmer D (2011) Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. Clin Cancer Res 17(10):3469\u20133477","journal-title":"Clin Cancer Res"},{"issue":"15","key":"1446_CR36","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Cutsem Van","year":"2011","unstructured":"Van Cutsem E, K\u00f6hne CH, L\u00e1ng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29(15):2011\u20132019","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-012-1446-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00384-012-1446-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-012-1446-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T07:14:13Z","timestamp":1687331653000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00384-012-1446-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,20]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["1446"],"URL":"https:\/\/doi.org\/10.1007\/s00384-012-1446-2","relation":{},"ISSN":["0179-1958","1432-1262"],"issn-type":[{"value":"0179-1958","type":"print"},{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,20]]}}}